Cargando…

Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery

The epidermal growth factor–epidermal growth factor receptor (EGF-EGFR) pathway has become the main focus of selective chemotherapeutic intervention. As a result, two classes of EGFR inhibitors have been clinically approved, namely monoclonal antibodies and small molecule kinase inhibitors. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furman, Olga, Zaporozhets, Alisa, Tobi, Dror, Bazylevich, Andrii, Firer, Michael A., Patsenker, Leonid, Gellerman, Gary, Lubin, Bat Chen R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318536/ https://www.ncbi.nlm.nih.gov/pubmed/35890400 http://dx.doi.org/10.3390/pharmaceutics14071505

Ejemplares similares

Theranostic system for ratiometric fluorescence monitoring of peptide-guided targeted drug delivery
por: Rozovsky, Alex, et al.
Publicado: (2019)

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells
por: Kalimuthu, Kalishwaralal, et al.
Publicado: (2018)

Effect of Solubilizing Group on the Antibacterial Activity of Heptamethine Cyanine Photosensitizers
por: Semenova, Olga, et al.
Publicado: (2023)

Targeted drug delivery for cancer therapy: the other side of antibodies
por: Firer, Michael A, et al.
Publicado: (2012)

Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
por: Gilad, Yosi, et al.
Publicado: (2016)

Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma
por: Redko, Boris, et al.
Publicado: (2016)

Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: antitumor activity in mouse melanoma models
por: Yacobovich, Shiri, et al.
Publicado: (2016)

Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse Model
por: Levi, Bar, et al.
Publicado: (2021)

Designing coarse grained-and atom based-potentials for protein-protein docking
por: Tobi, Dror
Publicado: (2010)

Dynamics based clustering of globin family members
por: Tobi, Dror
Publicado: (2018)

Recruitment of rare 3-grams at functional sites: Is this a mechanism for increasing enzyme specificity?
por: Tobi, Dror, et al.
Publicado: (2007)

Dynamical comparison between Drosha and Dicer reveals functional motion similarities and dissimilarities
por: Aharoni, Rotem, et al.
Publicado: (2019)

The effect of dimerization and ligand binding on the dynamics of Kaposi's sarcoma‐associated herpesvirus protease
por: Bern, David, et al.
Publicado: (2022)

Summary of Session III
por: Furman, M A
Publicado: (2002)

Facile Access to Fe(III)-Complexing Cyclic Hydroxamic Acids in a Three-Component Format
por: Chupakhin, Evgeny, et al.
Publicado: (2019)

EGFR(vIII): An Oncogene with Ambiguous Role
por: Rutkowska, Adrianna, et al.
Publicado: (2019)

Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization
por: Dratviman-Storobinsky, Olga, et al.
Publicado: (2009)

Click Conjugation of Boron Dipyrromethene (BODIPY) Fluorophores to EGFR-Targeting Linear and Cyclic Peptides
por: Williams, Tyrslai M., et al.
Publicado: (2021)

Motivación y productividad
por: Gellerman, Saul W.
Publicado: (1978)

La administración de las relaciones humanas
por: Gellerman, Saul W.
Publicado: (1970)

The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Gold(I) and Gold(III) Complexes of Cyclic (Alkyl)(amino)carbenes
por: Romanov, Alexander S., et al.
Publicado: (2015)

Control of cyclic oligoadenylate synthesis in a type III CRISPR system
por: Rouillon, Christophe, et al.
Publicado: (2018)

The Energy of Muscle Contraction. III. Kinetic Energy During Cyclic Contractions
por: Ross, Stephanie A., et al.
Publicado: (2021)

The Cyclic Oligoadenylate Signaling Pathway of Type III CRISPR-Cas Systems
por: Huang, Fengtao, et al.
Publicado: (2021)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis
por: Cao, Xinyu, et al.
Publicado: (2011)

Different sea urchin RAG-like genes were domesticated to carry out different functions
por: Yakovenko, Iryna, et al.
Publicado: (2023)

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
por: Gilad, Yosi, et al.
Publicado: (2021)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Chau, Nicole G, et al.
Publicado: (2011)

Ring nucleases deactivate Type III CRISPR ribonucleases by degrading cyclic oligoadenylate
por: Athukoralage, Januka S, et al.
Publicado: (2018)

Cyclic GMP dependent protein kinase (PKG) as a mediator of EGFR-induced apoptosis in breast cancer
por: Jackson, Nicole M, et al.
Publicado: (2015)

Disrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage
por: Pernicone, Nomi, et al.
Publicado: (2022)

One-photon scattering by an atomic chain in a two-mode resonator: cyclic conditions
por: Sizhuk, Andrii S, et al.
Publicado: (2014)

Neuroprotective Effect of Hyperbaric Oxygen Therapy on Anterior Ischemic Optic Neuropathy
por: Avraham-Lubin, Bat-Chen R., et al.
Publicado: (2011)

Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
por: Stec, Wojciech, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_squqhtqr2kb7uo7m5bmladkvar